Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
Clamp, Andrew R
AffiliationPrincess Margaret Cancer Centre, Toronto, ON, Canada
MetadataShow full item record
AbstractThe prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR inhibitors show clinical activity in endometrial cancer.
CitationRandomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. 2015: J Clin Oncol
JournalJournal of Clinical Oncology